key: cord-0758942-efnvjpad authors: Ismail, Zainab; Aborode, Abdullahi Tunde; Oyeyemi, Ajagbe Abayomi; Khan, Hiba; Hasan, Mohammad Mehedi; Saha, Anwesha; Akah, Blessing title: Impact of COVID‐19 pandemic on viral hepatitis in Africa: Challenges and way forward date: 2021-08-30 journal: Int J Health Plann Manage DOI: 10.1002/hpm.3317 sha: 0fbb6790cdcc43f195570a10a6908f14bdf393ca doc_id: 758942 cord_uid: efnvjpad With the overwhelming COVID‐19 pandemic in Africa, many other severe epidemics have been given low priority, such as viral hepatitis. Patient mortality due to viral hepatitis has raised concern to COVID‐19 patients due to compromise with undiagnosed hepatitis in Africa. The pandemic has worsened the control of the viral hepatitis epidemic as healthcare control facilities have moved their focus towards curbing COVID‐19 infections. However, different challenges have arisen to viral hepatitis patients because of low health attention that declines the progress of already diagnosed hepatitis patients. Follow‐up plans, routine testing and treatment plans for viral hepatitis are no longer as strict with the human resources transferred towards combating the pandemic. Thus, a global effort is required to abide by renewed recommendations to eradicate viral hepatitis in Africa that also fit the current picture of the COVID‐19 pandemic. The article discusses the current challenges viral hepatitis patients faced during the COVID‐19 pandemic and important recommendations that can see through these challenges in Africa. Africa's healthcare workforce and testing capabilities are insufficient to integrate the COVID-19 pandemic and other viral infection surveillance. [9] [10] [11] [12] [13] Particularly, in low-and middle-income countries, the inability of researchers and health authorities to predict the evolution of the COVID-19 pandemic in the long-term has escalated a chain reaction of crises in the healthcare system. 14, 15 Moreover, Individuals with chronic liver disease have been added to those at risk with increased danger for critical expression of COVID-19 as recommended by the US Centres for Disease Control and Prevention. 3 However, the existence of viral hepatitis does not directly escalate vulnerability in comparison to the SARS-CoV-2. The high occurrence of poor medical diagnosis among individual living with viral hepatitis in sub-Saharan Africa could be linked to the lack of SARS-CoV-2 infection restriction guidelines. 3 Late presentation or under-diagnosis of viral hepatitis disease in sub-Saharan Africa can be traced to the unrest in the health care delivery system during COV-ID-19, where the channelling of laboratory equipment, infrastructure and manpower is relocated for the sole purpose of COVID-19. 3 Consequently, study reports have disclosed the highest mortality rate (32.2 moralities per 100,000 Africa: Challenges and way forward population) among individuals in sub-Saharan Africa by viral hepatitis-associated liver disease (liver cirrhosis) due to the late diagnosis of hepatitis during the COVID-19 pandemic. With most medical services directed to contain the expanding COVID-19 pandemic, viral hepatitis patients face several challenges. The pandemic affected routine health services used to detect early stage and asymptomatic viral hepatitis. This is corroborated as the report from Tanzania and Gambia revealed the pro-tem closure of hepatitis clinics at the end of March 2020, in which health workers were transferred to assist COVID-19 preparedness. 16 Physicians were relocated as frontline health workers to respond to patients infected with the COVID-19 pandemic leaving the viral hepatitis centres in shortage. Patients decreased their routine follow-up visits due to the fear of getting infected with COVID-19 from the medical staff and health centres. 16 Travel restrictions limited patient's accessibility to essential investigations such as ultrasonography and nucleic acid tests, which are performed at the major centres exclusively. 3, 17 Some countries, such as Burkina Faso in the West of Africa, reported a shortage of antiviral medications due to flight suspension leading to treatment interruptions. 16 Temporarily, some clinics and follow-up centres were closed due to the fear of infecting others with COVID-19. 16 While telemedicine is encouraged globally as an effective alternative connection between patients and health services, Africa is affected by poor infrastructure, unstable Internet connections and limited access to smartphones and laptops making it less effective than it is in high and middle-income counties. The lockdown increased the number of home deliveries; subsequently, fewer infants got the hepatitis B virus vaccine. 3 The COVID-19 situation had a negative impact on viral hepatitis services globally. 17 This includes the decrease in patient checkups, reallocation of medical staff and travel restrictions which resulted in delayed diagnosis leading to delayed interventions and consequently more complications and costs. The interrupted treatment leaves patients liable to liver decompensation, cirrhosis and progression to hepatocellular carcinoma. 3 With fewer children getting the hepatitis B virus vaccine, it risks the viral hepatitis elimination program goal and losing a good shot for a hepatitis-free world. 18 The world's change of focus to COVID-19 risks adds more pressure on health services by the consequences of neglecting the viral hepatitis patients. At the time of the Ebola outbreak in 2014, non-Ebola consequences exceeded the consequences from the Ebola outbreak itself due to the same mistakes that are presently being made. 19 has caused around 88.000 deaths to date; on the other hand, the hepatitis virus causes 200,000 deaths a year. That is why viral hepatitis should have special attention regardless of the pandemic. The prevalence usage of herbal preparations to treat disease in Africa is due to inadequate access to healthcare services and cultural components amplified during the COVID-19 pandemic. Due to the challenges mentioned above, liver impairment (viral hepatitis and drug-induced liver injury) from hepatotoxic herbal treatment intake is predicted to be at its peak in African patients after the pandemic. 20 Despite the temporary closure of health centres against chronic diseases in Burkina Faso, hepatologists encouraged people to stick to their routine visits as best as possible. Although some crucial diagnostic tests such as polymerase chain reaction, ultrasonography and liver biopsy may not be available for everyone, primary health care units work hard to keep rapid tests for HBsAg, blood tests, and liver enzymes available. 16 On a positive note, some volunteering activities such as the NoHep organisation emerged to spread awareness about viral hepatitis with the same goal: to eliminate viral hepatitis by 2030. 21 Countries are paying more attention to the necessity of telemedicine and working to overcome its obstacles. Following the blueprint of the WHO on the eradication of viral hepatitis globally, the preliminary goals are on 90% depletion in the number of novel infections by 2030 and a 65% curtailment in the number of mortalities is imperative. 4 The establishment of the Africa hepatitis eradication initiatives and development of the WHO's global health sector strategy on viral hepatitis in African countries should also be strongly imposed. With the advancement of hepatitis-related mortalities, the following recommendations should be applied with the consideration of global collaboration: 1. Hepatologists should follow the recommendations of AASLD Expert Panel consensus statement in handling viral hepatitis patients during the COVID-19 pandemic. 22 2. Health authorities should support decentralised care in collaboration with hepatologists. 3. Improve the infrastructure to pave the way to efficient telemedicine services in diagnosis, management plans, drug prescription and follow-up. 7. It is highly recommended to encourage hepatic patients to get the available COVID-19 vaccines as they are classified as vulnerable population. 23 There is a need for viral hepatitis patients to get free accessibility to the COVID-19 and hepatitis vaccine; separate programmes should be set for such interventions. The importance of the COVID-19 vaccine cannot be stressed enough especially for vulnerable populations with comorbidities. Low-income countries are already suffering from COVID-19 vaccine shortage and should be prioritised in eliminating vaccine nationalism. 15 8. Ensure more strategic investments in hepatitis services. 9 . Strengthen the disease surveillance that detects viral hepatitis and COVID-19 synonymously. 10 . Educate healthcare providers and the communities in Africa on reducing the health disparities between COV-ID-19 and viral hepatitis. 11. Enhance infection control practice; education, oversight and enforcement, which is critical to reducing transmission of viral hepatitis in health care settings. 12. Collaborate locally with stakeholders, partners and communities disproportionately affected by viral hepatitis as well as other allies, to support observances by organising local events and awareness activities. 18. Transmission of viral hepatitis B and C in health care settings can be eliminated through rigorous application of universal precautions for all invasive medical interventions, promotion of injection safety measures and securing a safe supply of blood products. 19 . Effective interventions should be combined and tailored for the specific population, location and setting to have the most significant impact. For example, in certain countries with a high prevalence of hepatitis B virus, the most significant public health benefit would be: reducing deaths by preventing early life infection through birth-dose and childhood vaccination and the consistent treatment of chronic hepatitis patients. 20 . The actual public health dimension and impact of hepatitis epidemics are poorly understood in many countries. There is a need for national and regional awareness to strengthen their inadequate data and weak hepatitis surveillance programs, which will strengthen the plan for focused action and prioritise the allocation of resources. 21 . Ensure that hepatitis medicines are affordable and that those in need of treatment should have access to those medicines without experiencing financial hardship. Despite the primary concern of COVID-19, viral hepatitis is still an ongoing epidemic that requires serious medical attention with routine checkups. Many lives are hanging, waiting for medical diagnosis, treatment and follow-up. Health authorities should find a way to prioritise viral hepatitis patients despite the limited medical resources. Otherwise, we risk overwhelming the health systems during their most fragile state with complicated hepatic cases. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study Converging pandemics: implications of COVID-19 for the viral hepatitis response in sub-Saharan Africa Improving care of migrants is key for viral hepatitis elimination in Europe Epidemiological data for hepatitis D in Africa -authors' reply WHO Director-General's Opening Remarks at the Media Briefing on COVID-19 -11 COVID-19 research in Africa World Health Organization. WHO Coronavirus (COVID-19) Dashboard with Vaccination Data Impact of poor disease surveillance system on COVID-19 response in Africa: time to rethink and rebuilt Viral infections amidst COVID-19 in Africa: implications and recommendations The spread of Yellow fever amidst the COVID-19 pandemic in Africa and the ongoing efforts to mitigate it Lassa fever and COVID-19 in Africa: a double crisis on the fragile health system Measles returns to the Democratic Republic of Congo: a new predicament amid the COVID-19 crisis SARS-CoV-2 pandemics: the lack of critical reflection addressing short-and long-term challenges The precariousness of political management of the SARS-CoV-2 pandemic in the search for scientific answers: calling for prudence in public health emergencies Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa The impact of COVID-19 on hepatitis elimination COVID-19 and viral hepatitis elimination programs: are we stepping backward? Liver Int The economic and social burden of the 2014 Ebola outbreak in West Africa Comorbidities and the COVID-19 pandemic dynamics in Africa NOhep -The Global Movement to Eliminate Viral Hepatitis by 2030 Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement US Center of Disease Control and Prevention. Underlying Medical Conditions for Clinicians